Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
about
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.Neonatal abstinence syndrome after methadone or buprenorphine exposureTwo cases of intranasal naloxone self-administration in opioid overdose.Buprenorphine for opioid dependenceThe relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sampleAcute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Low-dose naloxone provides an abuse-deterrent effect to buprenorphineBuprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Factors associated with complicated buprenorphine inductionsSublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusersNarrative review: buprenorphine for opioid-dependent patients in office practice.The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome.The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review.The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings.Increasing diversion of methadone in Vancouver, Canada, 2005-2015.Management of opioid use disorders: a national clinical practice guideline.Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.
P2860
Q30276657-50BBC0FD-6E33-418F-A922-078DA1B97995Q30499416-A6327341-F451-4516-BB6A-F0FC45F07D9AQ33606282-AF9E659E-68E8-4764-A346-39731F1D3ABEQ34119459-436BD263-17C5-4BBC-8900-89E9CC41B46CQ34119478-E24DC1DE-2FD6-428B-ABCC-F9AF987C4A56Q34138291-372FD6A6-D08F-403C-9494-3CCF703F60C7Q34253036-65B6F3F3-7BB3-4B69-9559-F63536E4551AQ35575641-ED65D5BA-93F2-403E-B4FB-B495AAF220CBQ35863900-1A8A8CE4-5884-466D-A859-5C064891366DQ36265260-9681B70C-770D-4F22-831E-A6836519742BQ36394429-1CD8B8D7-861F-4609-B065-81B2D0EA2FFFQ36585261-9FF34E57-0F6A-4640-9C1F-88138990AF54Q36779246-1BC1E8B0-5DE2-44E5-81BF-155AE2410125Q36803326-7D224EED-C0A8-4FFE-8702-41F2D9CFBA69Q36959052-451AC6A9-D0F6-4A87-9F3E-DA6C0DCF91BCQ37180966-588B5C88-FE3D-4358-B9BF-DABD52E604E8Q38038363-EDCF4BAA-CECF-49AE-9968-061D0D5AFF75Q38379235-DE18E3B3-F7AD-4330-A839-FBBD55A83CA5Q38417339-D93EC502-BF58-40C3-A29C-FAA429C8D121Q38634946-71A8920C-870F-4FB0-9753-C063928F0F6BQ38695672-991196C8-C897-450F-ABD3-E26FD0929D76Q40468239-C046EF63-53A8-4B94-BA67-2DB987FB11F9Q47226505-188AB4EA-87A1-44EE-9E0E-3A27982C0749Q52316126-D0D1E52D-9512-4368-9D9A-7E49F813D964Q52601899-E3FABFA2-3D51-4249-BCDA-9C070C0A86CD
P2860
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@ast
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@en
type
label
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@ast
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@en
prefLabel
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@ast
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@en
P2093
P2860
P1476
Sublingual buprenorphine/nalox ...... d on 100mg of daily methadone.
@en
P2093
Eric C Strain
George E Bigelow
James Rosado
Sharon L Walsh
P2860
P304
P356
10.1016/J.DRUGALCDEP.2007.04.006
P577
2007-05-22T00:00:00Z